ADHD Treatment in Maplewood, NJ

ADHD is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity-impulsivity, or both, at levels disproportionate to developmental stage and causing functional impairment across two or more settings (school or work, home, relationships). Contrary to the public perception that it's a childhood condition children grow out of, adult ADHD is real, common (roughly 4.4% of U.S. adults meet diagnostic criteria), and among the most treatable psychiatric conditions we see. It also has the largest treatment effect size of any class of psychiatric medication — stimulants produce a greater symptom improvement than antidepressants produce in depression.

At Maplewood Mental Health Clinic, ADHD treatment starts with a real evaluation, not an assumption that stimulant medication is the answer. The first visit is a 60–90-minute assessment, follow-up care is substantive, and medication decisions happen inside an ongoing clinical relationship. That matters because attention problems can also come from anxiety, depression, bipolar disorder, trauma, sleep disruption, substance use, or medical issues.

This page covers how we actually diagnose and treat ADHD at our Maplewood office and over NJ-wide telehealth, following APSARD's first-ever adult ADHD guideline (2024) and AAP guidance for adolescents. It also addresses specific questions that come up for patients navigating current New Jersey Schedule II rules, the Ryan Haight Act, ongoing stimulant shortages, and the intersection of ADHD with anxiety, depression, and bipolar disorder.

Stimulant side effects are predictable, usually mild, and largely manageable. The most common are reduced appetite (especially around lunch; resolves by dinner for most), mild sleep onset delay (take the dose earlier in the day), transient headache (resolves within 1–2 weeks), mild blood pressure and heart rate elevation (clinically insignificant for most patients; monitored at visits), and occasional dry mouth. Rebound symptoms — an irritability or low mood window as the medication wears off in the evening — can occur with short-acting stimulants and are usually addressed by switching to an extended-release formulation or timing adjustment.

Less common but important: cardiovascular effects warrant a baseline EKG in patients with family history of sudden cardiac death, known structural heart disease, or significant cardiovascular risk factors. Current guidelines do not recommend routine EKG screening in otherwise healthy patients, but we gather cardiovascular history at every intake. Stimulants are contraindicated in patients with uncontrolled hypertension, advanced coronary disease, hyperthyroidism, or current glaucoma. Tics — either new-onset or worsening of pre-existing tics — can occur with stimulants; most resolve with dose reduction or formulation switch.

Ongoing monitoring includes blood pressure and heart rate at every visit, weight in adolescents and growth in pre-adolescents, sleep quality, and mood. We re-administer the ASRS or Conners at intervals to track symptom response quantitatively. If cardiovascular numbers drift upward, we address it — either through lower dosing, a formulation switch, or primary-care coordination.

Adolescents (ages 12–17). ADHD in this age range frequently overlaps with anxiety, depression, learning differences, and early substance use — all of which we screen for at intake. Treatment usually combines medication with behavioral strategies tuned to academic and social demands. The AAP recommends stimulants as first-line for adolescents with consideration of non-stimulants for specific contraindications. We see patients 12 and older; for children under 12, we refer to child-psychiatry colleagues.

Adults.Adult ADHD often shows up as career underperformance despite high intelligence, chronic late assignments, forgotten appointments, impulsive decisions that produce recurring negative outcomes, difficulty with organization at home, and in many cases a co-occurring anxiety or depressive disorder that has been treated (often inadequately) without recognition of the underlying ADHD. APSARD's 2024 guideline is the first dedicated adult-ADHD practice guideline and has modernized treatment expectations — many adult ADHD patients are treated to substantial functional improvement, not just “managed.”

Older adults. ADHD does not disappear with age. Older adults with persistent ADHD often present with decades of under-treatment, sometimes with compensatory strategies that are breaking down as cognitive reserve shifts. Medication choice in older adults weighs cardiovascular risk more heavily; non-stimulants may be preferred for patients with significant cardiovascular history. We assess for emerging cognitive impairment (mild cognitive impairment, early dementia) carefully in this population, because new-onset inattention in an older adult is more likely cognitive decline than ADHD.

Girls and women are systematically under-diagnosed with ADHD, for reasons that are now well-understood. The classic childhood ADHD picture — a hyperactive-impulsive boy who can't sit still — doesn't match most female presentations, which tend toward the inattentive subtype: daydreamy, quiet, disorganized, but not disruptive. School systems and clinicians trained on the hyperactive presentation miss the inattentive one. Many women arrive at our clinic in their thirties or forties having spent decades compensating through above-average intelligence and conscientiousness, hitting the wall when job complexity or family demands exceed the compensation capacity.

ADHD in women is also commonly comorbid with anxiety and depression, and it is frequently the ADHD that has been overlooked while the anxiety-and-depression label has been carried for years. Hormonal fluctuations (menstrual cycle, perimenopause) affect ADHD symptom severity — estrogen has dopaminergic effects, and the perimenopause transition in particular is a time when previously-compensated ADHD often becomes unmanageable. We think carefully about these patterns in every adult-woman intake.

ADHD stimulant prescribing sits at the intersection of federal and state regulations. The current rules in New Jersey are:

Adults on Schedule II stimulants. An initial in-person evaluation at our Maplewood office is required before Schedule II prescribing begins. After the first in-person visit, routine medication-management visits can be conducted via telehealth. Quarterly in-person follow-up visits are required for the duration of Schedule II treatment.

Patients under 18. New Jersey includes a minor-patient exception when the clinician uses interactive, real-time audio-video technology and obtains written parent or guardian consent waiving the in-person requirement. In practice, many adolescent patients still benefit from at least one in-person visit, but the regulatory flexibility exists.

NJ Prescription Drug Monitoring Program (NJ PDMP). Before every Schedule II prescription, we check the NJ PDMP — a regulatory requirement and a safety check that helps identify concurrent controlled-substance prescribing from other providers, doctor-shopping patterns, or potential diversion concerns. Patterns that emerge prompt a conversation, not a reflexive denial.

Stimulant shortages. The Adderall and Vyvanse shortages that began in 2022 continue in 2026 with episodic supply disruptions. When a preferred medication is unavailable, we work with you to identify equivalent alternatives (generic methylphenidate ER, Concerta, Focalin XR, AZSTARYS, alternative amphetamine formulations) and coordinate with pharmacies to find the closest in-stock option. Combination regimens with non-stimulant augmentation sometimes let us use lower stimulant doses that are easier to source during shortages.